NeuroSense Therapeutics Ltd.
NRSN Nasdaq
SEC CIK 1875091
Follow NeuroSense Therapeutics Ltd.
Weekly email: filings, results
Net income
−$11.3M
+8.6% vs prior year
EPS, diluted
−$0.83
+22.4% vs prior year
Operating cash flow
−$8.5M
−11.4% vs prior year
Operating income
−$13.3M
+1.8% vs prior year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY23 | −$11.3M |
| FY22 | −$12.3M |
| FY21 | −$4M |
| FY20 | −$2.8M |
| FY19 | −$1.2M |
| FY18 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY23 | −$8.5M |
| FY22 | −$7.7M |
| FY21 | −$1.6M |
| FY20 | −$704K |
| FY19 | −$589K |
| FY18 | - |